Everest Medicines Limited (HKG:1952)

Everest Medicines Revenue

In the year 2025, Everest Medicines had annual revenue of 1.71B CNY with 141.51% growth. Everest Medicines had revenue of 1.26B in the half year ending December 31, 2025, with 977.06% growth.

• Revenue: 1.71B CNY
• Revenue Growth: +141.51%
• P/S Ratio: 6.25
• Revenue / Employee: 2.10M CNY
• Employees: 812
• Market Cap: 11.86B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.71B	1.00B	141.51%
Dec 31, 2024	706.68M	580.75M	461.16%
Dec 31, 2023	125.93M	113.14M	884.46%
Dec 31, 2022	12.79M	12.74M	23,588.89%
Dec 31, 2021	54.00K	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 2, 2026

Data Sources Report a data error